Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	5 November 2026
Date of last disclosure:	18 September 2026

Director or senior manager giving disclosure

Full name(s):	Andrew Robert Donald Somervell
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Vice President - Products & Technology

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest

For that relevant interest-

Number held in class before acquisition or disposal:	155,763 Ordinary Shares
Number held in class after acquisition or disposal:	155,763 Ordinary Shares
Current registered holder(s):	Andrew Robert Donald Somervell
Registered holder(s) once transfers are registered:	Andrew Robert Donald Somervell

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	

For that derivative,-

Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	One

Details of transactions requiring disclosure-

Date of transaction:	5 November 2026

Nature of transaction:	Shares transferred from trustee to individual following completion of restrictive period for 2023 Employee Share Purchase Plan.
Name of any other party or parties to the transaction (if known):	Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	NZD $497.41
Number of financial products to which the transaction related:	48 Ordinary Shares

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:	
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:	a) Performance Share Rights b) Options to acquire Ordinary Shares
Nature of relevant interest:	Beneficial Interest

For that relevant interest,-

Number held in class:	a) 50,419 Performance Share Rights b) 27,504 Options to acquire Ordinary Shares
Current registered holder(s):	Andrew Robert Donald Somervell

For a derivative relevant interest,-

Type of derivative:	


Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	

or

Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	5 November 2026
Name and title of authorised person:	Raelene Leonard, General Counsel & Company Secretary